Immunome announced positive clinical trial results for its drug Varegacestat.

Data shows that the therapy not only achieved statistically significant improvement in the primary efficacy endpoint, but also demonstrated statistically significant positive changes in all predefined key secondary efficacy endpoints. This result signifies an important advancement for the candidate drug within the relevant therapeutic field.